Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Anne‐Michelle Noone

Biographic Data

ID7846571
NAMEAnne‐Michelle Noone
GIVEN NAMESAnne‐Michelle
FAMILY NAMENoone
SIGNATURENOONE A M
AFFILIATIONSNational Cancer Institute
ORCID0000-0001-6997-4004
VERIFIEDYes
TOTAL WORKS4
TOTAL CITATIONS0
AUTHOR COUNT4
EDITOR COUNT0
FIRST PUBLICATION YEAR2011
LATEST PUBLICATION YEAR2025
H-INDEX0
  • Compliance With Recommendations of the Surveillance, Epidemiology, and End Results (Seer) Treatment Data Use Agreement

    Yoon Duk Hong, Angela B Mariotto et al.•ARTICLE•Medical Care•2025•References: 3

    INTRODUCTION: The Surveillance, Epidemiology, and End Results (SEER) Program collects data on the first course of cancer treatment, but no and unknown receipt of treatment cannot be distinguished for radiation therapy (RT) and chemotherapy. As part of the Data Use Agreement (DUA), users must acknowledge that they understand the data limitations and agree to include a description of the limitations in any analyses published using the data. The obj…

  • Comparison of Seer Treatment Data With Medicare Claims

    Open Access•Anne-Michelle Noone, Anne‐Michelle Noone et al.•ARTICLE•Medical Care•2016•References: 19

    BACKGROUND: The population-based Surveillance, Epidemiology, and End Results (SEER) registries collect information on first-course treatment, including surgery, chemotherapy, radiation therapy, and hormone therapy. However, the SEER program does not release data on chemotherapy or hormone therapy due to uncertainties regarding data completeness. Activities are ongoing to investigate the opportunity to supplement SEER treatment data with other dat…

  • Physicians’ Beliefs About Breast Cancer Surveillance Testing are Consistent With Test Overuse

    Paul K J Han, Carrie N Klabunde et al.•ARTICLE•Medical Care•2013•References: 42

    BACKGROUND: Overuse of surveillance testing for breast cancer survivors is an important problem but its extent and determinants are incompletely understood. The objectives of this study were to determine the extent to which physicians' breast cancer surveillance testing beliefs are consistent with test overuse, and to identify factors associated with these beliefs. METHODS: During 2009-2010, a cross-sectional survey of US medical oncologists and …

  • Information Channels Associated with Awareness of Human Papillomavirus Infections and Vaccination among Latino Immigrants from Safety Net Clinics

    Open Access•Noel T Mueller, Anne‐Michelle Noone et al.•ARTICLE•Journal of Immigrant and Minority…•2011

No prominent works on this page.

  • Information Channels Associated with Awareness of Human Papillomavirus Infections and Vaccination among Latino Immigrants from Safety Net Clinics

    Open Access•Noel T Mueller, Anne‐Michelle Noone et al.•ARTICLE•Journal of Immigrant and Minority…•2011

  • Physicians’ Beliefs About Breast Cancer Surveillance Testing are Consistent With Test Overuse

    Paul K J Han, Carrie N Klabunde et al.•ARTICLE•Medical Care•2013•References: 42

    BACKGROUND: Overuse of surveillance testing for breast cancer survivors is an important problem but its extent and determinants are incompletely understood. The objectives of this study were to determine the extent to which physicians' breast cancer surveillance testing beliefs are consistent with test overuse, and to identify factors associated with these beliefs. METHODS: During 2009-2010, a cross-sectional survey of US medical oncologists and …

  • Comparison of Seer Treatment Data With Medicare Claims

    Open Access•Anne-Michelle Noone, Anne‐Michelle Noone et al.•ARTICLE•Medical Care•2016•References: 19

    BACKGROUND: The population-based Surveillance, Epidemiology, and End Results (SEER) registries collect information on first-course treatment, including surgery, chemotherapy, radiation therapy, and hormone therapy. However, the SEER program does not release data on chemotherapy or hormone therapy due to uncertainties regarding data completeness. Activities are ongoing to investigate the opportunity to supplement SEER treatment data with other dat…

  • Compliance With Recommendations of the Surveillance, Epidemiology, and End Results (Seer) Treatment Data Use Agreement

    Yoon Duk Hong, Angela B Mariotto et al.•ARTICLE•Medical Care•2025•References: 3

    INTRODUCTION: The Surveillance, Epidemiology, and End Results (SEER) Program collects data on the first course of cancer treatment, but no and unknown receipt of treatment cannot be distinguished for radiation therapy (RT) and chemotherapy. As part of the Data Use Agreement (DUA), users must acknowledge that they understand the data limitations and agree to include a description of the limitations in any analyses published using the data. The obj…

Cancer (3 works) · Global Cancer Incidence and Screening (3 works) · Internal Medicine (3 works) · Medicine (3 works) · Breast cancer (2 works) · Family medicine (2 works) · Internal Medicine (2 works) · MEDLINE (2 works) · Acknowledgement (1 works) · Advanced Causal Inference Techniques (1 works)

Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae